[1] |
MOMBELLI M, KAMPOURI E, MANUEL O. Influenza in solid organ transplant recipients: epidemiology, management, and outcomes[J]. Expert Rev Anti Infect Ther, 2020, 18(2): 103-112. DOI: 10.1080/14787210.2020.1713098.
|
[2] |
MARINELLI TM, KUMAR D. Influenza virus infection and transplantation[J]. Transplantation, 2021, 105(5): 968-978. DOI: 10.1097/TP.0000000000003486.
|
[3] |
Columbia University Kidney Transplant Program. Early description of coronavirus 2019 disease in kidney transplant recipients in New York[J]. J Am Soc Nephrol, 2020, 31(6): 1150-1156. DOI: 10.1681/ASN.2020030375.
|
[4] |
AKALIN E, AZZI Y, BARTASH R, et al. COVID-19 and kidney transplantation[J]. N Engl J Med, 2020, 382(25): 2475-2477. DOI: 10.1056/NEJMc2011117.
|
[5] |
KENNEDY J. Vaccine hesitancy: a growing concern[J]. Paediatr Drugs, 2020, 22(2): 105-111. DOI: 10.1007/s40272-020-00385-4.
|
[6] |
DANZIGER-ISAKOV L, KUMAR D, AST ID Community of Practice. Vaccination of solid organ transplant candidates and recipients: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice[J]. Clin Transplant, 2019, 33(9): e13563. DOI: 10.1111/ctr.13563.
|
[7] |
徐胜勇, 张秋彬, 李克莉, 等. 疫苗接种不良事件紧急处理中国急诊专家共识[J]. 中国急救医学, 2021, 41(2): 93-100.XU SY, ZHANG QB, LI KL, et al. Consensus of Chinese emergency experts on emergency management of vaccination adverse events[J]. Chin J Crit Care, 2021, 41(2): 93-100.
|
[8] |
Guidelines for vaccination of solid organ transplant candidates and recipients[J]. Am J Transplant, 2004, 4(Suppl 10): 160-163. DOI: 10.1111/j.1600-6135.2004.00737.x.
|
[9] |
AVERY RK, MICHAELS M. Update on immunizations in solid organ transplant recipients: what clinicians need to know[J]. Am J Transplant, 2008, 8(1): 9-14. DOI: 10.1111/j.1600-6143.2007.02051.x.
|
[10] |
RUBIN LG, LEVIN MJ, LJUNGMAN P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host[J]. Clin Infect Dis, 2014, 58(3): 309-318. DOI: 10.1093/cid/cit816.
|
[11] |
KUMAR D, FERREIRA VH, BLUMBERG E, et al. A 5-year prospective multicenter evaluation of influenza infection in transplant recipients[J]. Clin Infect Dis, 2018, 67(9): 1322-1329. DOI: 10.1093/cid/ciy294.
|
[12] |
国家免疫规划技术工作组流感疫苗工作组. 中国流感疫苗预防接种技术指南(2020-2021)[J]. 中华流行病学杂志, 2020, 41(10): 1555-1576. DOI: 10.3760/cma.j.cn112338-20200904-01126.Influenza Vaccine Working Group of National Immunization Program Technical Working Group. Technical guidelines for seasonal influenza vaccination in China (2020-2021)[J]. Chin J Epidemiol, 2020, 41(10): 1555-1576. DOI: 10.3760/cma.j.cn112338-20200904-01126.
|
[13] |
DENDLE C, STUART RL, MULLEY WR, et al. Pneumococcal vaccination in adult solid organ transplant recipients: a review of current evidence[J]. Vaccine, 2018, 36(42): 6253-6261. DOI: 10.1016/j.vaccine.2018.08.069.
|
[14] |
ERIKSSON M, KÄYHTY H, SAHA H, et al. A randomized, controlled trial comparing the immunogenecity and safety of a 23-valent pneumococcal polysaccharide vaccination to a repeated dose 13-valent pneumococcal conjugate vaccination in kidney transplant recipients[J]. Transpl Infect Dis, 2020, 22(4): e13343. DOI: 10.1111/tid.13343.
|
[15] |
中华预防医学会, 中华预防医学会疫苗与免疫分会. 肺炎球菌性疾病免疫预防专家共识(2020版)[J]. 中华流行病学杂志, 2020, 41(12): 1945-1979. DOI: 10.3760/cma.j.cn112338-20201111-01322.Chinese Preventive Medicine Association, Vaccine and Immunology Branch of the Chinese Preventive Medicine Association. Expert consensus on immunoprophylaxis of pneumococcal disease (2020 version)[J]. Chin J Epidemiol, 2020, 41(12): 1945-1979. DOI: 10.3760/cma.j.cn112338-20201111-01322.
|
[16] |
MILLER-HANDLEY H, PAULSEN G, HOOPER DK, et al. Durability of the hepatitis B vaccination in pediatric renal transplant recipients[J]. Clin Transplant, 2018, 32(5): e13247. DOI: 10.1111/ctr.13247.
|
[17] |
MOAL V, MOTTE A, VACHER-COPONAT H, et al. Considerable decrease in antibodies against hepatitis B surface antigen following kidney transplantation[J]. J Clin Virol, 2015, 68: 32-36. DOI: 10.1016/j.jcv.2015.04.011.
|
[18] |
WATKINS SL, ALEXANDER SR, BREWER ED, et al. Response to recombinant hepatitis B vaccine in children and adolescents with chronic renal failure[J]. Am J Kidney Dis, 2002, 40(2): 365-372. DOI: 10.1053/ajkd.2002.34521.
|
[19] |
GÜNTHER M, STARK K, NEUHAUS R, et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients[J]. Transplantation, 2001, 71(3): 477-479. DOI: 10.1097/00007890-200102150-00023.
|
[20] |
中国疾病预防控制中心. 狂犬病预防控制技术指南(2016版)[J]. 中国病毒病杂志, 2016, 6(3): 161-188. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201603001.htmChinese Center for Disease Control and Prevention. Technical guidelines for human rabies prevention and control (2016 edition)[J]. Chin J Viral Dis, 2016, 6(3): 161-188. https://www.cnki.com.cn/Article/CJFDTOTAL-ZRYX201603001.htm
|
[21] |
王传林, 刘斯, 邵祝军, 等. 外伤后破伤风疫苗和被动免疫制剂使用指南[J]. 中国疫苗和免疫, 2020, 26(1): 111-115, 127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202001023.htmWANG CL, LIU S, SHAO ZJ, et al. Guidelines for post-traumatic use of tetanus vaccines and passive immune preparations[J]. Chin J Vaccin Immun, 2020, 26(1): 111-115, 127. https://www.cnki.com.cn/Article/CJFDTOTAL-ZGJM202001023.htm
|
[22] |
LARSEN HK, THOMSEN LT, HAEDERSDAL M, et al. Risk of genital warts in renal transplant recipients-a registry-based, prospective cohort study[J]. Am J Transplant, 2019, 19(1): 156-165. DOI: 10.1111/ajt.15056.
|
[23] |
AZZI Y, BARTASH R, SCALEA J, et al. COVID-19 and solid organ transplantation: a review article[J]. Transplantation, 2021, 105(1): 37-55. DOI: 10.1097/TP.0000000000003523.
|
[24] |
NASRALLAH MM, OSMAN NA, ELALFY M, et al. Transplantation in the era of the COVID-19 pandemic: how should transplant patients and programs be handled?[J]. Rev Med Virol, 2021, 31(1): 1-9. DOI: 10.1002/rmv.2149.
|
[25] |
RAJA MA, MENDOZA MA, VILLAVICENCIO A, et al. COVID-19 in solid organ transplant recipients: a systematic review and Meta-analysis of current literature[J]. Transplant Rev (Orlando), 2021, 35(1): 100588. DOI: 10.1016/j.trre.2020.100588.
|
[26] |
TID COVID-19 guidance focused review: SARS-CoV-2 vaccines in transplant recipients[EB/OL]. [2021-09-30]. https://tts.org/26-tid/tid-resources/850-tid-covid-19-guidance-focused-review-sars-cov-2-vaccines-in-transplant-recipients.
|
[27] |
BOYARSKY BJ, WERBEL WA, AVERY RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients[J]. JAMA, 2021, 325(17): 1784-1786. DOI: 10.1001/jama.2021.4385.
|
[28] |
BENOTMANE I, GAUTIER-VARGAS G, COGNARD N, et al. Low immunization rates among kidney transplant recipients who received 2 doses of the mRNA-1273 SARS-CoV-2 vaccine[J]. Kidney Int, 2021, 99(6): 1498-1500. DOI: 10.1016/j.kint.2021.04.005.
|
[29] |
KAMAR N, ABRAVANEL F, MARION O, et al. Three doses of an mRNA COVID-19 vaccine in solid-organ transplant recipients[J]. N Engl J Med, 2021, 385(7): 661-662. DOI: 10.1056/NEJMc2108861.
|
[30] |
ALEJO JL, MITCHELL J, CHIANG TP, et al. Antibody response to a fourth dose of a SARS-CoV-2 vaccine in solid organ transplant recipients: a case series[J]. Transplantation, 2021, 105(12): e280-e281. DOI: 10.1097/TP.0000000000003934.
|
[31] |
BOYARSKY BJ, OU MT, GREENBERG RS, et al. Safety of the first dose of SARS-CoV-2 vaccination in solid organ transplant recipients[J]. Transplantation, 2021, 105(5): e56-e57. DOI: 10.1097/TP.0000000000003654.
|
[32] |
OU MT, BOYARSKY BJ, CHIANG TPY, et al. Immunogenicity and reactogenicity after SARS-CoV-2 mRNA vaccination in kidney transplant recipients taking belatacept[J]. Transplantation, 2021, 105(9): 2119-2123. DOI: 10.1097/TP.0000000000003824.
|
[33] |
OU MT, BOYARSKY BJ, MOTTER JD, et al. Safety and reactogenicity of 2 doses of SARS-CoV-2 vaccination in solid organ transplant recipients[J]. Transplantation, 2021, 105(10): 2170-2174. DOI: 10.1097/TP.0000000000003780.
|
[34] |
AL KAABI N, ZHANG Y, XIA S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial[J]. JAMA, 2021, 326(1): 35-45. DOI: 10.1001/jama.2021.8565.
|
[35] |
JARA A, UNDURRAGA EA, GONZÁLEZ C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile[J]. N Engl J Med, 2021, 385(10): 875-884. DOI: 10.1056/NEJMoa2107715.
|
[36] |
疾病预防控制局. 新冠病毒疫苗接种技术指南(第一版)[EB/OL]. [2021-09-30]. http://www.nhc.gov.cn/jkj/s3582/202103/c2febfd04fc5498f916b1be080905771.shtml.
|
[37] |
Centers for disease control and prevention[EB/OL]. [2021-09-30]. https://www.cdc.gov/DataStatistics/.
|
[38] |
ESOT congress 2021[EB/OL]. [2021-09-30]. https://www.esotcongress.org/.
|